Mutations in the SACS gene have been initially reported in a rare autosomal recessive cerebellar ataxia syndrome featuring prominent cerebellar atrophy, spasticity and peripheral neuropathy as well as retinal abnormalities in some cases (autosomal recessive spastic ataxia of Charlevoix-Saguenay, ARSACS). In the past few years, the phenotypic spectrum has broadened, mainly owing to the availability and application of high-throughput genetic testing methods. We identified nine patients (three sib pairs, three singleton cases) with isolated, non-syndromic hereditary motor and sensory neuropathy (HMSN) who carried pathogenic SACS mutations, either in the homozygous or compound heterozygous state. None of the patients displayed spasticity or pyramidal signs. Ataxia, which was noted in only three patients, was consistent with a sensory ataxia. Nerve conduction and nerve biopsy studies showed mixed demyelinating and axonal neuropathy. Brain MRI scans were either normal or revealed isolated upper vermis atrophy of the cerebellum. Our findings confirm the broad clinical spectrum associated with SACS mutations, including pure polyneuropathy without characteristic clinical and brain imaging manifestations of ARSACS.
Introduction
Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is a childhood-onset neurodegenerative disease (Bouchard et al. 1998; Vermeer et al. 1993) . It was originally described in the Charlevoix-Saguenay-Lac-Saint-Jean Electronic supplementary material The online version of this article (https ://doi.org/10.1007/s0043 9-018-1952-6) contains supplementary material, which is available to authorized users.
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region of Quebec in the northeast of Canada (De Braekeleer et al. 1993 ), but later turned out to be a panethnic condition, affecting individuals all over the world (Vermeer et al. 1993) . The "classical" phenotype of ARSACS is characterized by progressive spinocerebellar ataxia, upper motor neuron dysfunction with spasticity and peripheral neuropathy. Patients from Quebec show additional retinal involvement (hypermyelination of the retinal fibers and thickening of the peripapillar retinal layer), which are rarely found in patients from other regions. Brain MRI findings in patients with ARSACS typically show cerebellar atrophy, pontine hypointensities and hyperintensities of the lateral pons merging into the (thickened) middle cerebellar peduncles (Synofzik et al. 2013; Palmio et al. 2016; Tzoulis et al. 2013; Liu et al. 2016) . ARSACS is caused by biallelic variants in the SACS gene on chromosome 13q12.12, encoding the large sacsin protein, which is expressed in neurons in brain motor systems and various other tissues (Engert et al. 2000; Lariviere et al. 2015) .
Following identification of the SACS gene, more recent studies have expanded the genetic and clinical spectrum. Several patients with SACS variants missing cardinal symptoms or with later onset of disease have been reported, while others had additional autonomic dysfunction, hearing loss and neuropsychiatric disorders (Synofzik et al. 2013; Duquette et al. 2013; Pyle et al. 2012; Miyatake et al. 2012; Pilliod et al. 2015; Van Damme et al. 2009; Bradshaw et al. 2016) . Among individuals with a variant clinical presentation were four cases from three families with an isolated sensorimotor neuropathy (Synofzik et al. 2013; Souza et al. 2018) , leading to the initial diagnosis of hereditary motor and sensory neuropathy (HMSN, also known as Charcot-Marie-Tooth disease, CMT). Here, we report a series of nine additional patients from six families with biallelic SACS-mutations and an HMSN phenotype.
Materials and methods

Patient cohort
Four patients (one sib pair) from three unrelated families (A-C) were found in a cohort of 123 pediatric patients with inherited neuropathies cared for in the center for neuromuscular disorders in childhood, Dr. v. Hauner children's hospital of LMU Munich University Hospital. Five additional patients (two sib pairs) from three unrelated families (D-F) were referred to the neuromuscular genetics laboratory of the Friedrich-Baur-Institute at the Department of Neurology of LMU Munich University Hospital. Pedigrees of all families are provided in Fig. 1 . All participants or in case of children their legal representatives provided informed consent for the collection of samples, DNA analyses as well as for retrieval, analysis and publication of genetic and clinical data. The attending physicians of all patients were experienced neurologists or neuropediatricians. The study was approved by the local ethics committee .
Molecular genetic analysis
Whole-exome sequencing of the DNA sample of A-II.2 and subsequent read alignment and variant filtering were performed as previously reported (Chen et al. 2015) . For genetic testing of families B and C, a custom-made multigene panel was used that covered 64 genes for inherited neuropathies and related conditions, including SACS. Targeted enrichment was performed using the HaloPlex Target Enrichment System (Agilent Technologies, Santa Clara, USA) with an input of 50 ng DNA. After library pooling, next-generation sequencing was run on an Illumina platform (MiSeq NextSeq500 System, San Diego, USA) with 150 bp (bp) paired-end reads. An average coverage of at least 300× of the target regions including coding exons and 25 bp of flanking intronic sequence was aimed at. Sequences were evaluated by using the software SeqPilot of JSI (http://www.jsi-medis ys.de) including the module SeqNext. Generated fastQ-files were aligned to the human reference genome hg19/GRCh37. Molecular genetic studies of families D-F involved a combination of targeted linkage analysis/homozygosity mapping (Fischer et al. 2012 ) and gene-by-gene Sanger sequencing, following phenotype-guided algorithms (Rudnik-Schoneborn et al. 2016) . A genomic deletion (encompassing exons 3 and 4 of SACS, family D) was detected using a primer walking strategy and amplification of deletion-specific junction fragments as previously described Bergmann et al. 2003) .
Segregation of variants in the families was tested with Sanger sequencing of relevant exons and intron regions (families A, B, C, E, F) or amplification of deletion-specific junction fragments (family D) whenever DNA samples of parents were available.
An overview of genetic testing procedures is provided in Supplementary Table 1.
Nerve biopsy studies
A sural nerve biopsy had been obtained from one case (B-II.2) in the past for diagnostic purposes. Standard histology and electron microscopy of the glutaraldehydefixed, resin-embedded specimens was performed as described previously (Schroder et al. 1996) .
Results
SACS mutations
We identified mutations in the SACS gene in six unrelated families with suspected HMSN. All patients carried biallelic mutations, either in a homozygous (families B, D and E) or compound heterozygous state (families A, C and F) (Fig. 1, Supplementary Table 1 ). Altogether, we discovered a total of nine different mutations. Eight micromutations involved one or few bases, including four frameshift variants, three nonsense mutations and one missense mutation. In addition, an 8,581-bp genomic deletion encompassing SACS exons 3 and 4 was found, predicted to lead to a premature stop codon as splicing of exon 2 to exon 5 disrupts the open reading frame. Five of these mutations, including the single missense variant, had been reported previously in patients with a "classical" ARSACS 
Clinical presentation
All patients had the diagnosis of HMSN based on clinical and electrophysiological findings before SACS mutations were found. Clinical, electrophysiological and neuroradiological findings are provided in Table 1 .
Most patients came to medical attention in their first 2 years of life. One patient (C II.1) had later onset at age 15 years. No exact data were available for family F, but onset in childhood was concluded from medical reports. Most frequent presenting symptoms were delayed early motor development, tiptoe walking or gait instability. One patient (C II.1) presented initially with numbness in median-and ulnar-innervated areas, leading to suspicion of carpal and cubital tunnel syndrome. Disease progression was generally slow. Independent ambulation was preserved in all patients at last examination (age range 5-48 years); the oldest patient was using walking aids. A video documenting the gait of patient A-II:2 is available as Supplementary Video File.
On clinical examination, 7/9 patients had weakness of the foot extensors, 6/9 pes cavus and one pes planus. Intrinsic hand muscles were affected in 7/9 cases. Proximal muscles were normal in all individuals but patient F-II.1, who showed a 4/5 MRC paresis in the thigh musculature. Vibration sense was reduced (4/8-6/8 at the ankles) in 6/9 patients. Pain sensation was normal in all patients. Neither spasticity nor pyramidal tract signs were observed in any affected individual. Although generally mild, nystagmus (6/9 cases), tremor (1/9 cases), dysmetria (2/9 cases) and ax. axonal; dem. demyelinating, F female, M male, mo month(s), ND not done, NR not reported, y years dysarthria (1/9 cases) suggested subtle cerebellar involvement, while ataxia (3/9 cases) was mainly afferent and thus considered related to sensory neuropathy. Deep tendon reflexes were normal in 3/9, absent at the ankles in 2/9 and completely missing in 4/9 patients. No autonomic dysfunction, hearing loss and neuropsychiatric disorders were noted. Ophthalmoscopic examination in patient A II.2 showed normal ocular fundus findings. In families A-E, neurological examination of the parents was normal. Parents in family F were not examined in this study.
Electrophysiological findings
Motor and sensory nerve conduction studies showed combined demyelination and axonal loss in peripheral nerves of all eight cases that underwent neurophysiological examination (Table 1 , detailed electrophysiological data can be found in Supplementary Table 2 ). Motor nerve conduction velocities (NCV) in arm nerves ranged from 31 m/s to 44 m/s and from 20 m/s to 44 m/s in the lower extremities. Peroneal compound muscle action potentials (CMAPs) were absent in three patients. Nerve action potentials from sensory nerves (SNAPS) were absent in 7/9 cases.
Brain imaging
Brain MRI was performed in 7/9 cases ( Fig. 2; Table 1 ). Four of them showed normal findings (at age 6, 15, 16 and 30 years), two showed subtle atrophy of the superior cerebellar vermis (at age 10 and 19 years) and one individual had relevant upper vermis atrophy (at age 16 years). None of the patients had additional pathological findings on brain MRI scans. After detection of SACS mutations, MRI scans of patients A-II.2, B-II.2 and C-II.1 were re-evaluated for this study with regard to particular findings considered characteristic for ARSACS, i.e., linear T2 hypointensities in the pons, T2 hyperintensities in the lateral pons/middle cerebellar peduncles, atrophy of the parietal cortex and thin corpus callosum. No such changes were detected.
Sural nerve biopsy findings
A sural nerve biopsy (case B-II.2) revealed a moderate reduction in nerve fiber density. The remaining axons contained focal accumulations of autophagosomes and abnormal organelles (e.g., mitochondria). In addition, several large axons showed disproportionately thin myelin sheaths. There were few incipient Schwann cell onion bulb formations. Thickened and focally folded myelin sheaths were also repeatedly found. The number of unmyelinated axons was only moderately reduced (Fig. 3) .
Discussion
Most individuals with biallelic SACS mutations have spinocerebellar ataxia and atrophy complicated by spasticity, peripheral neuropathy and-largely confined to patients from Quebec-retinal abnormalities. In this study we report the clinical course as well as data from brain imaging, neurophysiological and histopathological examinations in a series of nine patients from six families with a diagnosis of HMSN, a non-syndromic inherited neuropathy, in which mutations in the SACS gene turned out to be the underlying cause.
HMSN represent a spectrum of monogenic disorders affecting the peripheral nervous system, characterized by muscle weakness and atrophy of distal limbs, diminished or absent deep tendon reflexes, foot deformities, gait problems and usually mild sensory deficits. The genetic diagnosis of inherited peripheral neuropathies is still challenging due to clinical and genetic heterogeneity. While more than 80 genes are associated with hereditary neuropathies, about half of the patients still do not have a definite genetic diagnosis (Weis et al. 2017; Rudnik-Schoneborn et al. 2017 ). This indicates that not all causative genes are known or that some changes in known genes are not detected by current diagnostic methods (e.g., genomic imbalances or deep intronic changes). Moreover, extensive molecular diagnostics, in particular whole-exome sequencing, have demonstrated that hereditary neuropathies can result from mutations in genes known to cause similar or related diseases (Weis et al. 2017; Rudnik-Schoneborn et al. 2017) . Likewise, isolated peripheral neuropathy can also be a minor variant of more complex neurodegenerative disorders: For instance, similar to the identification of SACS mutations in ARSACS and HMSN, variants in HADHB and MPV17, previously identified in syndromic diseases (Wanders et al. 1992; Spinazzola et al. 2006) , have been more recently reported in patients with pure sensorimotor neuropathy (Hong et al. 2013; Baumann et al. 2018; Choi et al. 2015) .
SACS mutations were first reported to cause ARSACS, which features progressive spinocerebellar ataxia and upper motor neuron dysfunction (Vermeer et al. 1993; Engert et al. 2000) . A peripheral neuropathy is probably present in all patients, but in "classical" cases the central nervous symptoms predominate. For long regarded as a disease restricted to the Quebec region due to founder mutations from French ancestors, ARSACS turned out to be a relatively frequent cause of spastic ataxia in many populations worldwide (Vermeer et al. 1993) . While most patients present with the triad of cerebellar ataxia, spasticity and peripheral neuropathy, more variable clinical presentations have been reported (Synofzik et al. 2013; Duquette et al. 2013; Baets et al. 2010 ), including few cases with an isolated or clearly predominating sensorimotor neuropathy (Synofzik et al. 2013; Souza et al. 2018) . Similarly, in our group of patients, symptoms of neuropathy were the reason to seek medical attention.
Mild ataxia, if present, was attributed to decreased sensory input as it worsened on eye closure (positive Romberg's sign) and sensory neurography showed abnormal findings. Obviously, after identification of SACS mutations, the neuroanatomic origin of ataxia has to be reconsidered, particularly because clinical reassessment revealed additional, though generally mild, cerebellar signs like nystagmus, tremor, dysmetria and dysarthria. None of our patients showed spasticity or pyramidal signs. Even though neuropathy was the leading symptom, this indicates that ARSACS encompasses a spectrum of disease ranging from non-syndromic polyneuropathy at the mild end to a neurological multisystem disorder at the severe extreme.
The clinical variability of the disease is also reflected by the cranial MRI findings. Patients with a full-blown ARSACS phenotype show cerebellar atrophy, T2-hypointensities in the pons (Shimazaki et al. 2013 ) and hyperintensities of the lateral pons merging into the (thickened) middle cerebellar peduncles, often combined with supratentorial brain abnormalities (bilateral parietal cerebral atrophy and thinning of the posterior midbody of the corpus callosum) (Synofzik et al. 2013 ). In our series, MRI was either normal (four patients) or showed isolated atrophy of the upper vermis but no further particularities (three cases).
Neurophysiological studies revealed a mixed demyelinating and axonal sensorimotor neuropathy, except for individual E II.1, where the neuropathy was predominantly demyelinating. Moreover, a diagnostic sural nerve biopsy from patient B-II.2, performed several years before discovery of the genetic cause, confirmed a combination of demyelinating and axonal abnormalities. Several earlier neurophysiological (Synofzik et al. 2013; Baets et al. 2010; Vermeer et al. 2008; Prodi et al. 2013 ) and nerve biopsy (Baets et al. 2010; El Euch-Fayache et al. 2003; Peyronnard et al. 1979 ) studies in ARSACS patients were also consistent with a mixed neuropathy in most cases, though signs of demyelination (Synofzik et al. 2013) or axonal loss (Souza et al. 2018 ) predominated in some.
The SACS gene is located on chromosome 13q12.12 and encodes the giant 521-kDa protein sacsin, which is mainly expressed in neurons. While the function of the protein is not yet fully understood, there is evidence for its involvement in the regulation of mitochondrial function (Lariviere et al. 2015; Criscuolo et al. 2015; Parfitt et al. 2009; Girard et al. 2012 ) and dynamics (Bradshaw et al. 2016 ). Thus, SACSrelated HMSN can be probably added to the growing group of inherited neuropathies that are caused by mitochondrial abnormalities such as those related to GDAP1 and MFN2 variants. More than 230 different SACS mutations have been identified so far (Human Gene Mutation database (http:// www.hgmd.cf.ac.uk)). Most variants were loss-of-function changes, but missense mutations affecting highly conserved residues do occur as well. Intragenic deletions, as observed in family D from our series, appear to be less frequent events but have been occasionally reported (Baets et al. 2010) .
Concerning genotype-phenotype interactions, previous studies (Synofzik et al. 2013; Souza et al. 2018 ) suggested preponderance for "milder" missense or in-frame indel mutations in individuals with a HMSN-presentation. However, the mutations which were found in our group of patients covered the whole spectrum of mutations (truncating, missense and exon-deletion mutations), and some of these mutations have already been described in "classical" ARSACS. The overlapping spectrum of mutations between our series and cases with the "classical" phenotype imply that the clinical phenotype cannot be predicted based on genetic findings.
It is certainly possible that patients with predominant neuropathy at disease onset will develop a full-blown ARSACS phenotype later in their life. Indeed, there have been reports of patients who were first diagnosed with ARSACS as adults, but retrospectively had experienced features of HMSN in childhood (e.g., delayed motor development, high arched feet) (Van Damme et al. 2009 ). In our series, more than half of the patients had already reached adulthood (the two oldest patients are already 39 and 48 years old) without significant multisystem pathology and without typical changes on brain MRI. These observations seem to support the existence of a constant neuropathy-predominant phenotype associated with SACS mutations.
In essence, this study provides further evidence that individuals harboring biallelic variants of the SACS gene can clinically present with an oligosymptomatic form of ARSACS syndrome, characterized by a predominant axonaldemyelinating sensorimotor neuropathy without spasticity and prominent ataxia. In this group of patients, cranial MRI seems to be normal or shows isolated atrophy of the superior cerebellar vermis, but none of the additional MRI findings considered characteristic in individuals with ARSACS. In this and previous studies (Synofzik et al. 2013; Souza et al. 2018) , SACS variants were found in HMSN patients from several different ethnic backgrounds. In our population of pediatric patients with hereditary neuropathies, the relative frequency of the SACS variants among all causes of HMSN was about 2.5%. We hypothesize that SACS variants account for a relevant proportion of HMSN cases, at least in pediatric cohorts, providing a rationale for including analysis of the SACS gene into diagnostic screening strategies for genetically unclassified HMSN patients.
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